Analystreport

Esperion Therapeutics (NASDAQ: ESPR) was downgraded by analysts at JPMorgan Chase from a "neutral" rating to an "underweight" rating.

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com